Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy

PHASE3CompletedINTERVENTIONAL
Enrollment

218

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
Cancer Prostate
Interventions
DRUG

Zoledronic acid

Trial Locations (19)

Unknown

Novartis Investigative Site, Anderlecht

Novartis Investigative Site, Antwerp

Novartis Investigative Site, Bruges

Novartis Investigative Site, Brussels

Novartis Investigative Site, Charleroi

Novartis Investigative Site, Edegem

Novartis Investigative Site, Ghent

Novaris Investigative Site, Gosselies

Novartis Investigative Site, Kortrijk

Novartis Investigative Site, Leper

Novartis Investigative Site, Leuven

Novaris Investigative Site, Libramont

Novartis Investigative Site, Mont-Godinne

Novartis Investigative Site, Roeselare

Novartis Investigative Site, Tongeren

Novartis Investigative Site, Tournai

Novartis Investigative Site, Turnhout

Novartis Investigative Site, Wilrijk

Novartis Investigative Site, Woluwe-Saint-Lambert

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY